Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Docetaxel in Advanced Pancreatic or Biliary Adenocarcinoma
NCT00268840Phase 2Completed
- Sponsor
- ARCAGY
- Start
- Aug 2001
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in pancreatic adenocarcinoma (PDAC) and biliary tract adenocarcinoma, sponsored by ARCAGY. Primary endpoint: Overall Response Rate. Started Aug 2001; status: completed.
02
Drugs
docetaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)biliary tract adenocarcinoma
Beyond the preview
Go deeper on NCT00268840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268840.